Procept Biorobotics Q3 revenue USD 98.291 million vs. IBES estimate USD 102.6 million

PRCT•2026-11-04

Procept Biorobotics reported Q3 revenue of USD 98.291 million, net income of USD -26.516 million and adjusted EBITDA of USD -9.822 million; it forecast FY gross margin of 65% and adjusted EBITDA of USD -35 million to USD -30 million.

1. Quarterly results and outlook

Q3 adjusted EBITDA was USD -9.822 million, compared with the IBES estimate of USD -5.68 million. Procept Biorobotics forecast FY adjusted EBITDA of USD -35 million to USD -30 million, versus the IBES estimate of USD -33.7 million.

Procept Biorobotics Q3 revenue USD 98.291 million vs. IBES estimate USD 102.6 million

1. Quarterly results and outlook

Related News

Motorola Solutions Q3 2026 net earnings fall 9% to $512 million

Acadia Pharmaceuticals Q3 revenue rises 23% on DAYBUE and NUPLAZID sales

Traeger Q3 revenue misses analyst expectations, dragged by consumables sector

AMC Entertainment to host third-quarter results webcast

Microsoft director Emma Walmsley does not seek re-election